We performed a Western blotting assay to confirm changes in STAT3 or NF-κB activity and found that the phosphorylation of STAT3 or IκB-α was prevented in AML-12 cells treated with two compounds, and statistical significance was confirmed in the group treated with 10 μM compounds. The gene discussed is NFKB1; the disease is acute myeloid leukemia.